Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Hospital Clínico Universitario de Valladolid
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06244823CT.gov The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab | — | Unknown | — | — | — |
NCT05281770CT.gov Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine With Aura
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fremanezumab (this asset) | Hospital Clínico Universitario de Valladolid | Approved | B · 62 |
| Topiramate | Tongji Hospital | P4 | BBB |
| DHE | Satsuma Pharmaceuticals, Inc. | P3 | BB |
| Apsolol | Norwegian University of Science and Technology | P3 | BB |
| Rimegepant | University of South Florida | P4 | BB |
| Dfn-11 (Sumatriptan Injection) | University of Aarhus | P3 | BB |
| Almotriptan | Messoud Ashina, MD | P4 | BB |
| Metoclopramide | Assistance Publique - Hôpitaux de Paris | P4 | BB |
| Tonabersat | Minster Research Ltd | P2 | B |
+40 more in the Migraine With Aura cohort
Other indications for Fremanezumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P4 | BBB · 74 |
| Sleep Disorder | — | P4 | BB · 65 |
| Migraine Without Aura | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fremanezumab in Migraine With Aura. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fremanezumab-migraine-with-aura
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →